Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757528 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| SCHEMBL242383 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| SCHEMBL13886182 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| SCHEMBL299755 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| SCHEMBL4213653 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| Hydrochloric Acid SCHEMBL242382 | 0.99 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| Hydrochloric Acid SCHEMBL242384 | 0.99 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| SCHEMBL1831645 | 0.95 | ADORA2A (0.45) | ADORA2AADORA3ADORA1 | |
| Hydrochloric Acid SCHEMBL4488897 | 0.94 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 | |
| Hydrochloric Acid SCHEMBL4488903 | 0.94 | ADORA2A (0.48) | ADORA2AADORA3ADORA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | claimed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | claimed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181934-A1 | Organic Compounds | LTB4R2, LTA4H, LTB4R | ADORA2A 28/4885ADORA3 43/4885ADORA1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.